Abstract
For the purpose of tumor dormancy therapy, UFT+Mitomycin C or TS-1 in patients with recurrent head and neck cancer was studied. Toxicity was not greater in the patients with a higher incidence of grade 2. One patient has survived for more than 4 years, having been given UFT+Mitomycin C at the beginning. For patients with lung metastasis, median survival time was 600 days, and time to progression was 4.5 months in the TS-1 group (n=4). TS-1 method was useful in terms of QOL. Based on these results, we believe that tumor dormancy therapy will be realized for the treatment of recurrent or lung metastastic head and neck cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
